SIGA PE Ratio & Valuation, Is SIGA Overvalued
SIGA Technologies Inc. (SIGA) is considered overvalued, with its current forward P/E ratio of 57.47 significantly exceeding its five-year average of 8.92. The fair price for SIGA is estimated to be between $0.90 and $1.63, starkly contrasting its current price of $5.24, indicating it is overvalued by 220.92%. The company's P/S ratio of 1.74, despite being lower than the competitor average, is deemed unsustainable given its robust revenue decline of -95.34%.
The Technical Signals Behind (SIGA) That Institutions Follow
This article provides a technical analysis of Siga Technologies Inc. (NASDAQ: SIGA) for institutional followers. It outlines key findings, AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging), and a multi-timeframe signal analysis indicating near-term strong sentiment but neutral mid and long-term outlooks, with elevated downside risk.
Q3 2025 SIGA Technologies Inc Earnings Call Transcript
SIGA Technologies Inc. (SIGA) reported strong financial results for the first nine months of 2025, with $86 million in product revenue and a robust cash position of $172 million. Despite a net loss in Q3 2025, the company is actively engaged with the US government for future antiviral treatments and advancing its pipeline, including pediatric and post-exposure prophylaxis programs. Shareholder value commitment is evident through $230 million returned since 2020 via dividends and share buybacks, though concerns include questions from the EMA regarding product efficacy and potential delays due to the US government shutdown.
Siga Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)
Siga Technologies (NASDAQ:SIGA) experienced unusually high options trading volume on Wednesday, with traders acquiring 1,200 call options, a 1,438% increase over average. This activity follows the company's declaration of a special dividend of $0.60 per share, payable on April 23rd to stockholders of record on April 7th. The specialty pharmaceutical company, known for its smallpox antiviral TPOXX, is currently rated "Hold" by analysts, and its stock is trading around $5.17 with a market capitalization of approximately $370.4 million.
SIGA Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for SIGA Technologies Inc. (SIGA), rating it a "Strong Sell" based on various technical indicators. It details moving averages, momentum indicators like RSI and MACD, and identifies key support and resistance levels for the stock. The analysis highlights that SIGA is trading below its significant moving averages, suggesting a bearish long-term trend.
SIGA SEC Filings - Siga Technologie 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Siga Technologie (SIGA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It details SIGA's financial condition, business activities, and material events, with AI-powered summaries to highlight key information from lengthy documents. The article mentions recent filings like the Q3 2025 earnings press release and insider trading activities.
Does SIGA (SIGA)’s Repeat Special Dividend Reveal a Deeper Shift in Its Capital Allocation Priorities?
SIGA Technologies Inc. recently declared a special cash dividend of US$0.60 per share, payable on April 23, 2026, crediting its strong balance sheet and ongoing work on smallpox preparedness. This repeat dividend underscores management's confidence in cash reserves and their ability to return capital even during slower sales periods, despite the inherent risks associated with unpredictable government contract visibility. Investors are encouraged to consider the company's reliance on a limited number of government buyers and various fair value estimates when evaluating the stock.
SIGA Technologies declares $0.60/share
SIGA Technologies announced a dividend of $0.60 per share. This declaration comes after the company's Q4 2023 earnings report highlighted a significant beat on revenue and EPS. This dividend underscores the company's financial performance and shareholder return strategy.
SIGA Technologies Declares Special One-Time Cash Dividend
SIGA Technologies has announced a special one-time cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026. This decision reflects the company's financial flexibility and a shareholder-focused capital allocation strategy. Analysts currently rate SIGA as a Hold with a $5.00 price target, acknowledging its financial strength and positive earnings outlook, despite weak technicals.
Why Are Siga Technologies Shares Trading Higher?
SIGA Technologies (NASDAQ:SIGA) shares are trading higher after the company announced a special cash dividend of $0.60 per share, consistent with the previous year's dividend. Despite a generally down market and a struggling healthcare sector, SIGA's stock is experiencing a technical rebound, potentially attracting short-term dip buyers after reaching oversold conditions. The company's immediate strength is seen as stock-specific within a weak sector, with future catalysts including an estimated earnings report on May 7, 2026.
Why Are Siga Technologies Shares Trading Higher?
SIGA Technologies (NASDAQ: SIGA) shares are trading higher after the company declared a special cash dividend of $0.60 per share, payable in late April. This dividend announcement, consistent with last year's, comes despite broader market weakness and positions SIGA as an outperformer in the healthcare sector today. While the stock shows signs of a technical rebound from oversold conditions, its intermediate trend remains downward.
EMA Recommends Discontinuation of Tecovirimat for Mpox Treatment
The European Medicines Agency (EMA) expert panel has recommended discontinuing Tecovirimat for mpox treatment due to insufficient efficacy, as clinical trials showed no significant improvement in healing lesions or other disease outcomes compared to a placebo. While the drug remains authorized for other viral conditions like smallpox and cowpox, this decision highlights its limitations specifically for mpox. SIGA Technologies, the developer, is still pursuing global expansion and anticipates an EMA decision regarding smallpox in March 2026.
Siga Technologies Inc. Plans Dividend of $0.60 (NASDAQ:SIGA)
Siga Technologies Inc. (NASDAQ:SIGA) has declared a dividend of $0.60 per share, payable on April 23rd to shareholders of record on April 7th. The stock recently opened at $4.96 with a market cap of $355.35 million and a PE ratio of 16.00. Analysts project 1.04 EPS for the current year, and Weiss Ratings recently upgraded the stock to a "hold."
SIGA Technologies declares $0.60 special dividend per share By Investing.com
SIGA Technologies has announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This dividend, matching the previous year's amount, reflects the company's strong balance sheet and commitment to shareholder value, despite the stock trading near its 52-week low. The pharmaceutical company, focused on infectious disease countermeasures, reported a Q4 2025 quarterly loss but an annual net income of $23 million with a solid cash balance.
SIGA Technologies declares $0.60 special dividend per share
SIGA Technologies (NASDAQ:SIGA) has announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record by April 7, 2026. This dividend, matching the 2025 level, reflects the company's strong balance sheet and commitment to shareholder value, offering a 12% yield. Despite trading near its 52-week low and a recent quarterly loss, the company maintains a robust cash balance and is considered undervalued by InvestingPro.
SIGA Technologies declares $0.60 special dividend per share By Investing.com
SIGA Technologies, Inc. (NASDAQ:SIGA) has announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This dividend matches the previous year's special dividend and reflects the company's strong balance sheet and focus on shareholder value, despite trading near its 52-week low. The company, a commercial-stage pharmaceutical firm, recently reported a Q4 2025 loss but demonstrated overall annual strength with a net income of $23 million and a solid cash balance.
SIGA Technologies (SIGA) General Counsel nets shares from RSU vesting
SIGA Technologies General Counsel Larry R. Miller reported the vesting of one-third of his previously granted restricted stock units, acquiring 6,920 shares of common stock. The company withheld 3,526 shares to cover tax obligations. Following these transactions, Miller directly holds 51,912 common shares, reflecting routine equity compensation rather than a market buy or sell.
SIGA Technologies declares $0.60/share
SIGA Technologies has declared a cash dividend of $0.60 per share. This declaration indicates a direct return of capital to shareholders. Further details about the record and payment dates would typically follow such an announcement.
SIGA Technologies Declares Special One-Time Cash Dividend
SIGA Technologies has announced a special one-time cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This move highlights the company's financial flexibility and commitment to returning capital to shareholders. TipRanks' AI Analyst, Spark, rates SIGA as Neutral, citing solid financials but tempered by weak technicals.
[8-K] SIGA TECHNOLOGIES INC Reports Material Event
SIGA Technologies, Inc. has declared a special, one-time cash dividend of $0.60 per share of its common stock. This dividend is payable on April 23, 2026, to shareholders of record as of April 7, 2026. This action signifies a direct cash return to existing shareholders, separate from any regular dividend policy.
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Technologies Inc. announced a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record on April 7, 2026. This dividend, consistent with the previous year's, reflects the company's strong balance sheet and commitment to shareholder value. CEO Diem Nguyen highlighted the company's focus on executing its strategy and strengthening preparedness for potential smallpox outbreaks.
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Technologies Inc. has declared a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026. This decision reflects the company's strong balance sheet and commitment to maximizing shareholder value, according to CEO Diem Nguyen. SIGA, a commercial-stage pharmaceutical company, focuses on developing medicines for infectious diseases, particularly orthopoxviruses, and works with governments to enhance preparedness for outbreaks.
Earnings call transcript: SIGA Technologies Q4 2025 shows mixed market reaction
SIGA Technologies reported mixed results for Q4 2025, with an EPS loss of -$0.08 but a strong annual net income of $23 million and $155 million in cash. The stock experienced an after-hours dip of 2.23% but rebounded 4.53% in premarket trading. The company remains focused on government partnerships, particularly for its TPOXX product, and is navigating regulatory uncertainties in Europe while pursuing new development programs.
SIGA Technologies (SIGA) Is Down 11.2% After Mixed 2025 Results And Renewed Mpox Focus – Has The Bull Case Changed?
SIGA Technologies reported mixed Q4 2025 results with a revenue of US$3.8 million and a net loss of US$5.4 million, though full-year 2025 was profitable with US$94.57 million in revenue and US$23.28 million in net income. The company's stock fell 11.2% following these results, despite renewed attention on its smallpox-related antiviral portfolio due to a severe mpox case in New York City. The investment narrative for SIGA depends on its ability to navigate unpredictable government stockpiling and clinical trial outcomes for its niche antiviral products.
SIGA Technologies (SIGA) Is Down 11.2% After Mixed 2025 Results And Renewed Mpox Focus – Has The Bull Case Changed?
SIGA Technologies (SIGA) saw an 11.2% dip after posting mixed Q4 2025 results, with a significant revenue drop for the quarter, though full-year financials remained profitable. The confirmed severe mpox case in New York City has reignited interest in SIGA's smallpox-related antiviral products. Investors are now evaluating if this renewed focus and potential for new contracts can outweigh the impact of lumpy government orders and past trial setbacks for TPOXX.
Stock Traders Purchase Large Volume of Siga Technologies Call Options (NASDAQ:SIGA)
Investors purchased a significantly increased volume of call options for Siga Technologies (NASDAQ:SIGA) on Wednesday, indicating unusual bullish activity. Several large institutional investors also recently boosted their stakes in the company, which now has 55.4% institutional ownership. Siga Technologies reported a quarterly EPS of -$0.08 and currently holds a consensus "Hold" rating from analysts after a recent upgrade from "sell" to "hold" by Weiss Ratings.
U.S. Smallpox Treatment Market: See Incredible Growth
A new research report by Coherent Market Insights projects substantial growth for the U.S. Smallpox Treatment Market from 2026 to 2033. The report analyzes key market trends, drivers, challenges, and the competitive landscape, emphasizing technological innovation, pricing trends, and investment potential. Leading companies in this market include Siga Technologies, Bavarian Nordic, and Emergent BioSolutions.
SIGA Technologies (SIGA) General Counsel gets RSUs, pays taxes in shares
SIGA Technologies General Counsel Larry R. Miller reported routine equity compensation activity. On March 13, 2026, 21,261 restricted stock units vested and were settled, with 11,187 shares withheld to cover tax obligations. Miller also received a new grant of 68,060 restricted stock units, which will vest in three equal annual installments.
SIGA Technologies (SIGA) CFO awarded RSUs and shares on vesting
Daniel J. Luckshire, Executive Vice President & CFO of SIGA Technologies, reported routine equity compensation activities involving Restricted Stock Units (RSUs). This included the vesting of 11,503 common shares from a previous RSU grant and a new RSU award of 55,228 units. Additionally, 6,074 shares were withheld by the company to cover tax obligations associated with the RSU vesting.
SIGA Technologies (SIGA) CEO Diem Nguyen reports RSU grant and tax withholding
SIGA Technologies CEO Diem Nguyen reported equity compensation activity, including the vesting of restricted stock units (RSUs) into 85,045 common shares and a new grant of 272,243 RSUs. The company withheld 47,029 shares at $5.26 each to cover tax obligations related to the RSU vesting. Following these transactions, Nguyen directly owns 138,767 common shares and holds 272,243 RSUs.
SIGA Technologies (SIGA) EVP receives RSU grant and stock withheld for taxes
Dennis E. Hruby, EVP and Chief Scientific Officer of SIGA Technologies, reported routine equity compensation activity including the vesting of 11,445 restricted stock units (RSUs) and a new grant of 54,942 RSUs. To cover tax obligations, 3,955 shares were withheld at $5.26 per share. Following these transactions, Hruby directly holds 198,537 common shares.
CSM Advisors LLC Has $5.46 Million Stake in Siga Technologies Inc. $SIGA
CSM Advisors LLC significantly increased its stake in Siga Technologies Inc. (NASDAQ:SIGA) by 66.5% during the third quarter, bringing their total holdings to 596,512 shares valued at $5.46 million. Other institutional investors also adjusted their positions in SIGA, with the company's stock currently 55.40% owned by institutional investors and hedge funds. Siga Technologies, a specialty pharmaceutical company focused on medical countermeasures, recently reported quarterly earnings of ($0.08) per share and has a "Hold" rating from one analyst.
Is It Time To Reassess SIGA Technologies (SIGA) After Recent Share Price Weakness?
This article analyzes SIGA Technologies (SIGA) after a recent share price decline. It uses a Discounted Cash Flow (DCF) model and P/E ratio comparison to suggest the stock is significantly undervalued by 59.8% based on the DCF, while its P/E ratio is about right when compared to the industry though well below peers. The report urges investors to consider various valuation perspectives and suggests the company's valuation score is 4 out of 6.
A Look At SIGA Technologies (SIGA) Valuation After 2025 Earnings, New TPOXX Orders And Funding
SIGA Technologies (SIGA) reported lower revenue and net income in its 2025 earnings but has received new government funding and international TPOXX orders, alongside pending European regulatory decisions. Despite recent share price pressure, the company's P/E ratio of 16.8x suggests it may be undervalued compared to peers and the broader pharmaceuticals industry, with the Simply Wall St DCF model estimating a fair value significantly higher than its current share price. The article highlights the balance between growth potential from new contracts and regulatory risks, particularly concerning TPOXX.
Technical Reactions to SIGA Trends in Macro Strategies
This article analyzes current trends for Siga Technologies Inc. (NASDAQ: SIGA) using AI models, indicating weak near and mid-term sentiment despite a strong long-term outlook. It outlines institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report highlights elevated downside risk due to a lack of additional long-term support signals.
SIGA Technologies (SIGA) Margin Compression Challenges Bullish Narratives After FY 2025 Results
SIGA Technologies (SIGA) reported mixed FY 2025 results, with Q4 revenue at US$3.8 million and a basic EPS loss of US$0.08, while full-year revenue was US$94.6 million and EPS was US$0.33. The company experienced significant margin compression, with net profit margin falling from 42.7% to 24.6%, and lumpy revenue, impacting profitability. Despite these concerns, SIGA's trailing P/E of 16.8x is below industry and peer averages, and its share price is significantly below its DCF fair value, suggesting a potentially undervalued stock even with recent performance challenges.
SIGA Reports Financial Results for Three and Twelve Months
SIGA Technologies Inc. reported its financial results for the three and twelve months ended December 31, 2025, generating $88 million in TPOXX product revenues for the year and $24 million in pre-tax operating income. The company secured an additional $27 million in U.S. Government funding for development activities and received a $13 million international procurement order for oral TPOXX in January 2026. SIGA anticipates the European Medicine Agency’s CHMP will maintain tecovirimat's indications for smallpox, cowpox, and vaccinia complications but recommend withdrawal of the mpox indication.
SIGA Technologies (SIGA) Is Down 9.2% After Steep Q4 Profit Drop Despite New Asia Pacific Contract
SIGA Technologies experienced a 9.2% drop in its stock price following a significant decline in Q4 2025 revenue and a swing to a net loss, despite securing a US$13 million oral TPOXX procurement order in the Asia Pacific region. The company's reliance on irregular government contracts makes its financial performance volatile. Investors are looking for additional contracts and clarity on capital returns, while the stock's fair value remains a concern.
SIGA Technologies (NASDAQ: SIGA) 2025 profit shrinks as revenue declines
SIGA Technologies reported a significant decline in its 2025 financial results, with total revenues dropping to $94.6 million from $138.7 million in 2024, leading to a net income of $23.3 million compared to $59.2 million previously. Despite the decline, the company remained profitable and secured $27 million in additional U.S. government funding and a $13 million oral TPOXX procurement order from an Asia Pacific customer in early 2026. The balance sheet remains strong with $154.9 million in cash and cash equivalents.
SIGA: 2025 delivered strong revenues, robust cash, and expanding global demand for TPOXX
SIGA Technologies (SIGA) reported strong financial performance in 2025, with $88 million in product revenues and $23 million in net income. The company ended the year with a robust cash balance of $155 million and no debt. Demand for its product TPOXX remains strong both domestically and internationally, with new multi-year contracts and ongoing regulatory engagement in key markets.
Earnings call transcript: SIGA Technologies Q4 2025 results show strong performance
SIGA Technologies Inc. reported strong financial results for Q4 and the full year 2025, with $95 million in total revenues primarily from product sales of TPOXX. The company maintains a robust financial position with $155 million in cash and no debt, driven by ongoing government partnerships and international market expansion. Discussions focused on strategic growth, continued government contracts, and development in pediatric and post-exposure prophylaxis programs for TPOXX.
SIGA Technologies 2025 10-K: Revenue $94.6M, EPS $0.32
SIGA Technologies reported total revenues of $94.6 million for 2025, a significant decline from the prior year, primarily due to lower product sales. Diluted earnings per share also decreased to $0.32, impacted by reduced government and international deliveries and increased R&D spending. The company continues to invest in IV manufacturing capacity and pediatric formulation development, heavily relying on a key U.S. government contract for TPOXX® deliveries.
SIGA Technologies Inc announced its financial results for the three months and full year ended December 31, 2025, and shared the latest business updates.
SIGA Technologies Inc. has released its financial results for the three months and full year ending December 31, 2025. The announcement includes key financial indicators and strategic development priorities, highlighting the company's resilience in the current market. This disclosure provides insight into SIGA Technologies' operational performance and future outlook.
SIGA Technologies Inc announced its financial results for the three months and full year ended December 31, 2025, and shared the latest business updates.
SIGA Technologies Inc. has announced its financial results for the three months and full year ending December 31, 2025. The company also provided updates on its business, highlighting key financial indicators and strategic development priorities. This disclosure aims to demonstrate the company's operational resilience within the current market landscape.
SIGA Technologies FY 2025 earnings preview
This article is a preview of SIGA Technologies' FY 2025 earnings. The content provided is minimal and does not offer specific details about the expected financial results or analysis.
SIGA Technologies Inc. Common Stock (SIGA) Stock Price Today & Analysis
This article provides an analysis of SIGA Technologies Inc. (SIGA) stock, highlighting its financial fundamentals, valuation metrics, and company overview. SIGA is a pharmaceutical company focused on the health security market, with its primary product being TPOXX for human smallpox. The content also includes FAQs about buying SIGA stock on Gotrade, minimum investment, dividend information, and market hours.
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
SIGA Technologies Inc. announced it will host a webcast and conference call on March 10, 2026, at 4:30 P.M. ET to provide a business update following the release of its 2025 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. A live webcast and replay will be available on the company's website.
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
SIGA Technologies, Inc. announced it will host a webcast and conference call on March 10, 2026, at 4:30 P.M. ET to provide a business update following the release of its 2025 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire, with details for live access and replay provided. SIGA is a pharmaceutical company focused on developing medicines to treat and prevent infectious diseases, particularly orthopoxviruses.
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
SIGA Technologies, Inc. announced it will host a webcast and conference call on March 10, 2026, at 4:30 P.M. ET to provide a business update following the release of its 2025 financial results. The call will feature CEO Diem Nguyen and CFO Daniel Luckshire, with a live webcast available on the company's website and a replay accessible for two weeks. SIGA is a commercial-stage pharmaceutical company focused on developing medicines for infectious diseases, particularly orthopoxviruses.
SIGA CEO to review 2025 results on March 10 investor call
SIGA Technologies, Inc. (Nasdaq: SIGA) announced that it will host a webcast and conference call on March 10, 2026, at 4:30 P.M. ET to provide a business update following the release of its 2025 financial results. CEO Diem Nguyen and CFO Daniel Luckshire will lead the call. Investors can access the live webcast through the company's website or join the conference call via provided dial-in numbers, with a replay available for two weeks.
